Organon (OGN) Common Equity (2020 - 2026)

Organon has reported Common Equity for 7 years, with the latest figure at $1.0 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 37.24% year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $1.0 billion, a 37.24% increase from a year earlier, with the FY2025 full-year figure at $752.0 million, up 59.32% from the prior year.
• Common Equity was $1.0 billion for Q2 2026 at Organon, up from $903.0 million in the prior quarter.
• The five-year high for Common Equity was $1.0 billion in Q2 2026, with the low at -$1.2 billion in Q1 2022.
• Average Common Equity over 5 years is -$16.5 million, with a median of $96.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity sank 126.47% in 2022, then jumped 1029.17% in 2025.
• Over 5 years, Common Equity stood at -$892.0 million in 2022, then jumped by 92.15% to -$70.0 million in 2023, then jumped by 774.29% to $472.0 million in 2024, then surged by 59.32% to $752.0 million in 2025, then surged by 33.78% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q2 2026), $903.0 million (Q1 2026), and $752.0 million (Q4 2025), per Business Quant data.